- Home
- NABL vs ETNB Comparison
NABL vs ETNB Comparison
Compare NABL & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NABL
- ETNB
- Stock Information
- Founded
- NABL 2000
- ETNB 2018
- Country
- NABL United States
- ETNB United States
- Employees
- NABL N/A
- ETNB N/A
- Industry
- NABL Computer Software: Prepackaged Software
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- NABL Technology
- ETNB Health Care
- Exchange
- NABL Nasdaq
- ETNB Nasdaq
- Market Cap
- NABL 1.5B
- ETNB 1.5B
- IPO Year
- NABL N/A
- ETNB 2019
- Fundamental
- Price
- NABL $7.92
- ETNB $8.87
- Analyst Decision
- NABL Buy
- ETNB Strong Buy
- Analyst Count
- NABL 4
- ETNB 10
- Target Price
- NABL $9.31
- ETNB $27.22
- AVG Volume (30 Days)
- NABL 721.9K
- ETNB 1.4M
- Earning Date
- NABL 08-07-2025
- ETNB 08-07-2025
- Dividend Yield
- NABL N/A
- ETNB N/A
- EPS Growth
- NABL N/A
- ETNB N/A
- EPS
- NABL 0.01
- ETNB N/A
- Revenue
- NABL $482,397,000.00
- ETNB N/A
- Revenue This Year
- NABL $9.54
- ETNB N/A
- Revenue Next Year
- NABL $8.71
- ETNB N/A
- P/E Ratio
- NABL $516.26
- ETNB N/A
- Revenue Growth
- NABL 7.40
- ETNB N/A
- 52 Week Low
- NABL $6.07
- ETNB $4.16
- 52 Week High
- NABL $13.12
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- NABL 51.12
- ETNB 43.45
- Support Level
- NABL $7.64
- ETNB $8.46
- Resistance Level
- NABL $8.12
- ETNB $9.47
- Average True Range (ATR)
- NABL 0.22
- ETNB 0.46
- MACD
- NABL 0.02
- ETNB -0.02
- Stochastic Oscillator
- NABL 71.92
- ETNB 33.33
About NABL N-able Inc.
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).